U.H. and M.W. contributed equally to this work.
Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations
Article first published online: 13 JAN 2014
© 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 170, Issue 1, pages 202–204, January 2014
How to Cite
Hüffmeier, U., Wätzold, M., Mohr, J., Schön, M.P. and Mössner, R. (2014), Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. British Journal of Dermatology, 170: 202–204. doi: 10.1111/bjd.12548
Funding sources: none.
Conflicts of interest: R.M. and M.P.S. have received payments for conduction of clinical trials, as invited speaker or advisor, or for travel grants from the following companies: Abbott GmbH & Co. KG, Biogen IDEC GmbH, Essex Pharma GmbH, Janssen-Cilag, LEO Pharma GmbH, Merck Serono GmbH, Novartis Pharma GmbH, Pfizer GmbH and Wyeth Pharma GmbH. M.P.S. has received research grants from Abbott and BiogenIdec, and has received consulting fees from Abbott, BiogenIdec, Janssen-Cilag, LEO Pharma, Novartis Pharma and Pfizer.
- Issue published online: 13 JAN 2014
- Article first published online: 13 JAN 2014
- Accepted manuscript online: 2 AUG 2013 01:37AM EST
- 4Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med 2010; 153:66–7., , et al.